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Objectives: Treatment resistant depression (TRD) is associated with higher dysfunction, 
morbidity and mortality and is more difficult and expensive to treat. However, only few 
studies investigated potential treatment strategies. The objective of this multicentre study was 
to prospectively evaluate TRD patients who previously did not respond to at least two 
previous antidepressants. 
Methods: Four hundred seventeen patients, who failed to respond to a previous 
retrospectively assessed antidepressant, were firstly included in a 6-week venlafaxine 
treatment; secondly, those who failed to respond were treated for further 6 weeks with 
escitalopram. 
Results: Out of 417 patients who had failed to respond to previous treatment, 334 completed 
treatment with venlafaxine to prospectively define TRD, with a dropout rate of 19.9%. In the 
intent to treat (ITT) population in the first phase of the trial, responders to venlafaxine were 
151 (36.21%) while remitters were 83 (19.90%). After phase one, 170 non responders, 
defined as TRD, were included in the second phase and 157 completed the course, with a 
dropout rate of 7.65%. Of the 170 ITT entering the second phase, responders to escitalopram 
were 71 (41.76%) while remitters were 39 (22.94%). After the third treatment, patients 
showed a dropout rate of 7.65% and  a rate of presence of at least one serious adverse event 
of 19.18%.  
Conclusions: The main finding of the paper is that relevant rates of response and remission 
may be observed after a third line treatment in patients resistant to two previous treatments.  
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Despite the available effective pharmacotherapeutic strategies to treat patients affected by 
Major Depressive Disorder (MDD), consistent unmet needs remain. In particular, a key issue 
is represented by the treatment choice for Treatment Resistant Depression (TRD) patients.   
Different definitions of TRD have been suggested (Berlim and Turecki 2007), from the lack 
of response to a single antidepressant (Souery, Amsterdam et al. 1999; Thase 2001; Fava 
2003), to the lack of response to two or more antidepressants of different classes (Thase 
2001; CHMP 2002). In particular, the most widely used definition has been proposed in the 
Committee for Medicinal Products for Human Use (CHMP) guidelines: “a patient is 
considered therapy resistant when consecutive treatment with two products of different 
classes, used for a sufficient length of time at an adequate dose, fail to induce an acceptable 
effect” (CHMP 2002), though this definition is not used in the CHMP concept paper and has 
been under revision due to current negative evidence about defining TRD by antidepressant 
classes. An increasing number of reports showed no advantage in favour of switching to a 
different class of antidepressant in patients with MDD (Ruhe, Huyser et al. 2006; Rush, 
Trivedi et al. 2006; Bschor and Baethge 2010; Souery, Serretti et al. 2011; Gaynes, Dusetzina 
et al. 2012). The issue remains controversial. 
Venlafaxine is a dual serotonin-norepinephrine reuptake inhibitor (SNRI) that has been 
reported to have higher efficacy in the treatment of MDD compared to selective serotonin 
reuptake inhibitors (SSRIs) but not to others (Stahl, Entsuah et al. 2002; Bauer, 
Tharmanathan et al. 2009; Cipriani, Furukawa et al. 2009). Some studies suggested that 
venlafaxine, due to its pharmacodynamic characteristics, could be an effective drug in TRD, 
with results supporting the efficacy and tolerability of venlafaxine in TRD patients who have 
not responded to previous treatments (de Montigny, Silverstone et al. 1999; Schweitzer, 
Page 6 of 42
URL: http:/mc.manuscriptcentral.com/swbp - e-mail: wfsbp@meduniwien.ac.at





























































For Peer Review Only
6 
 
Burrows et al. 2001; Saiz-Ruiz, Ibanez et al. 2002; Corya, Williamson et al. 2006; Fang, 
Yuan et al. 2010), including studies using high doses above the licensed range (450-600 mg) 
(Mbaya 2002). 
Escitalopram (Leonard and Taylor 2010; Kirino 2012; Zhong, Haddjeri et al. 2012) is a SSRI 
which has shown efficacy and safety in MDD treatment as well (Burke, Gergel et al. 2002; 
Stamouli, Yfantis et al. 2009). Efficacy and safety remained high when using doses up to 50 
mg (Wade, Crawford et al. 2011), as well as in studies with elderly populations (Chen, Huang 
et al. 2011). Escitalopram was found to have a superior efficacy in comparison with 
citalopram in particular (Cipriani, Santilli et al. 2009; Montgomery, Hansen et al. 2011) – 
explained by differences in the dynamics of serotonin transporter occupancy (Kasper, Sacher 
et al. 2009) – and in comparison with other SSRIs as well (Cipriani, Santilli et al. 2009; 
Kasper, Baldwin et al. 2009). The differences in efficacy appeared more clear-cut in severely 
depressed patients (Kennedy, Andersen et al. 2009; Ali and Lam 2011). When compared to 
venlafaxine or duloxetine (alone or pooled), escitalopram was found to be likewise more 
effective and better tolerated in MDD treatment (Montgomery and Andersen 2006; Kennedy, 
Andersen et al. 2009; Kornstein, Li et al. 2009). In a specific study, escitalopram was found 
to more likely result in remission without concurrent side effects in comparison with SNRIs 
(Signorovitch, Ramakrishnan et al. 2011). Moreover, escitalopram was found to be more 
effective than other antidepressant medications (citalopram, fluoxetine, paroxetine, sertraline, 
duloxetine and venlafaxine) in treating severely depressed patients (Bielski, Ventura et al. 
2004; Kennedy, Andersen et al. 2009; Kilts, Wade et al. 2009; Kornstein, Li et al. 2009) and 
patients who had not responded to a previous antidepressant (Lam, Lonn et al. 2010).  
To further evaluate the efficacy and tolerability of escitalopram in TRD, not considered in the 
STAR*D study, a prospective study was undertaken on a sample of 417 MDD patients 
resistant to at least two consecutive adequate antidepressant treatments (in terms of dose and 
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duration). In particular, patients who failed to respond to a previous retrospectively assessed 
antidepressant were entered into a multicentre multinational 2-phase trial: in the first phase 
patients received a 6-week venlafaxine treatment; in the second phase those who failed to 
respond to venlafaxine were treated for a further 6-week period with escitalopram.   
To the best of our knowledge, this is the first study to be primarily designed to evaluate 
escitalopram efficacy and tolerability in a sample of patients resistant to at least two adequate 




Four hundred seventeen MDD patients who failed to respond to a previous retrospectively 
assessed antidepressant (AD1, see Figure 1) were entered into an open multicentre 
multinational 2-phase trial: in the first phase patients received a 6-week venlafaxine treatment 
(AD2, Figure 1); in the second phase those who failed to respond to venlafaxine were treated 
for a further 6-week period with escitalopram (AD3, Figure 1).   
Patients were recruited from January 2005 to December 2011 in the context of the European 
multicenter project. Six centers took part in the project: 1) Department of Psychiatry, Erasme 
Hospital, Université Libre de Bruxelles, Brussels, Belgium; 2) Department of Biomedical and 
NeuroMotor Sciences, University of Bologna, Bologna, Italy; 3) Department of Psychiatry 
and Psychotherapy, Medical University Vienna, Austria; 4) Department of Psychiatry, Chaim 
Sheba Medical Center, Tel-Hashomer, Israel; 5) Elancourt, Toulouse and Sartrouville, 
France; 6) 1
st
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To be included in the 6 week prospective treatment with venlafaxine each patient had to: 1. 
be able to read and understand the patient information sheet; 2. have signed the informed 
consent form; 3. be an in- or outpatient, male or female, of at least 18 years of age; 4. have a 
Current Major Depressive Episode, assessed with the Mini International Neuropsychiatric 
Interview (MINI), moderate or severe, according to DSM-IV-TR criteria (classification 
codes: 296.2x or 296.3x); 5. have been treated for the Current Episode with any 
antidepressant (AD1) (other than escitalopram or venlafaxine) prescribed continuously at its 
optimal dose (Annex 1) for at least 4 weeks (criterion verified at screening) – if at inclusion 
the patient was not during AD1 period of any antidepressant, this period without 
antidepressant should not have exceeded 4 weeks); 6. be a non-responder to this previous 
treatment (AD1) (Montgomery Asberg Depression Rating Scale (MADRS) improvement 
<50%); 7. have a total score ≥22 on the MADRS. 
To be excluded from the study each patient had to: 1. have previously participated in this 
study; 2. be a non responder to a combination of 2 antidepressants (at least 2 weeks of 
treatment with an adequate dose for each of the 2 drugs) and/or to an augmentation therapy 
(at least 2 weeks with a potentiating agent at any dose) at the time of screening; 3. have a 
history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram 
or venlafaxine; 4. have one or more of the following conditions: a. any Current Psychiatric 
Disorder established as the principal diagnosis other than Major Depressive Disorder as 
defined in the DSM-IV-TR (assessed with the MINI); b. any Substance Disorder (except 
nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR; c. any 
severe Personality Disorder according to investigator clinical judgement that might 
compromise the study; 5. have received one or more of the following disallowed treatments: 
a. oral antipsychotic drugs had to have been stopped at least 2 weeks before inclusion; the 
patient could be included if the antipsychotic medication had been taken at infra-therapeutic 
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dose (lower than the recommended dose as indicated in the notice of the product); patients 
were excluded if they had received a depot antipsychotic preparation within the past 6 
months; b. ECT within the past 6 months; c. lithium, carbamazepine, lamotrigine, valproate 
or valpromide at therapeutic dose and for more than 2 weeks within the past month; d. 
benzodiazepines: more than 25 mg/day of diazepam or equivalent within the last week for 
chronic users of benzodiazepines (more than 3 months on treatment) and more than 10 
mg/day of diazepam or equivalent for non chronic users (less than 3 months); e. more than 20 
mg/day of zolpidem, 15 mg/day of zopiclone or 20 mg/day of zaleplon within the last week; 
f. any non-benzodiazepine anxiolytic within the last week; g. any serotonin agonist (e.g., 
triptans) within the last week; h. any other drug with potential psychotropic effects within the 
last week; i. any investigational product within 3 months prior to screening; j. escitalopram or 
venlafaxine at adequate dose and duration during the Current Episode; k. formal 
psychotherapy started in the month preceding inclusion; 6. have a previous history of 
convulsive disorder other than a single childhood febrile seizure; 7. present evidence of 
urinary retention or glaucoma; 8. have a serious illness and/or serious sequelae thereof, 
including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, 
endocrine, neurological, infectious, neoplastic, or metabolic disturbance; 9. have, in the 
opinion of the investigator (based on physical examination, medical history and vital signs), 
comorbid conditions(s) that would render inclusion in the study unsafe; 10. take medication 
that, in the opinion of the investigator, could interfere with the assessments of safety, 
tolerability, or efficacy; 11. in female patients, be pregnant or breastfeed at inclusion as well 
as during the study; 12. be, in the opinion of the investigator, unlikely to comply with the 
clinical study protocol or is unsuitable for any reason. 
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Patients meeting the above criteria and for whom the investigator considered switching to 
venlafaxine, were included in a 6 week prospective treatment with venlafaxine (AD2) 
prescribed continuously at its optimal dose. 
Initial venlafaxine daily dose was 75 mg; the daily dose could be further increased to 150 mg 
after 1 week, on the basis of an unsatisfactory response as judged by the investigator. If 
necessary, the dose could be increased up to a maximum of 225 mg, since in many countries 
this dose is the highest allowed and since there is no specific evidence that higher doses are 
more effective than 225 mg one. 
The aim of the venlafaxine phase of the trial was to prospectively define TRD.  
 
Escitalopram Treatment 
Patients considered as non responders at the end of the venlafaxine treatment were evaluated 
for inclusion in the second phase of the trial. To be eligible for inclusion in the 6-week 
prospective treatment with escitalopram (AD3) each patient had to meet 1 of the 2 following 
inclusion criteria: 
1. At day 28: the patient has a total score ≥20 on the MADRS and a decrease from start 
of the venlafaxine treatment in MADRS total score <25%; 
2. At day 42: patient has a total score ≥20 on the MADRS or a decrease from start of the 
venlafaxine treatment in MADRS total score <50%. 
Exclusion Criteria: any patient who met the following criteria at the end of the venlafaxine 
treatment was not included in the escitalopram treatment: 1. The patient had not taken AD2 
medication for three consecutive days or more, or overall compliance was less than 80% 
during the venlafaxine treatment; 2. any of the previously described exclusion criteria that 
appeared since the initiation of the venlafaxine treatment. 
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Initial escitalopram daily dose was 10 mg; the daily dose had to be increased to 20 mg after 1 
week; after 2 weeks, the daily dose could be further increased to 30 mg on the basis of an 
unsatisfactory response as judged by the investigator.  
The study protocol was approved by the Ethical Committees of all participating centres and it 
has been performed in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. Written informed consent was obtained from all participants prior to 
their inclusion in the study. 
 
Assessment 
To any patient meeting criteria for inclusion, once they had signed the inform consent, a 
baseline interview including the following modules was administered: 1. socio-demographic 
data; 2. MINI, version 5.0.0 modified for the group for the study of resistant depression 
(Souery, Oswald et al. 2007); 3. severity scales (baseline MADRS (Montgomery and Asberg 
1979), Hamilton Rating Scale for Depression (HRSD) 17-item version (Hamilton 1960), and 
Clinical Global Impression Severity (CGI-S) (Guy 1976)); 4. somatic illnesses; 5. current and 
6. previous medications; 7. side effects (Udvalg for Kliniske Undersøgelser (UKU) Side 
Effect Rating Scale (Lingjaerde, Ahlfors et al. 1987)); 8. psychiatric familial antecedents; 9. 
functional impairment (Sheehan Disability Scale (SDS) (Sheehan 1983)). The assessment 
was completed using “TRD.COM”, a centralized server consisting on a structured 
examination tool and immediate data capture. The MINI was administered to all patients. The 
MADRS, the HRSD, the CGI-S and CGI-I (Clinical Global Impression Improvement) scales, 
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The use of psychotropic drugs was not allowed during the period of the study except for: 
a. Chronic use of benzodiazepines (more than 3 months): 
1. Daily use of 25 mg of diazepam or equivalent was allowed, with the possibility to increase 
to 35 mg per day. 
2. Zolpidem, zopiclone or zaleplon were allowed, no more than zolpidem 20 mg/day, 
zopiclone 15 mg/day or zaleplon 20 mg/day. 
b. Patients free/non chronic users of benzodiazepines at inclusion: 
1. Daily use of up to 10 mg of diazepam or equivalent was allowed. 
2. Zolpidem, zopiclone or zaleplon were allowed, no more than zolpidem 20 mg/day, 
zopiclone 15 mg/day or zaleplon 20 mg/day. 
c. Deviation from these criteria was allowed up to 2 days, only once and at any time during 
the study. 
 
Switching strategies and therapeutic windows 
From AD1 to AD2: a maximum of 3 days of bitherapy was allowed. A maximum of 3 days 
of therapeutic window was allowed (except for MAOI: 2 weeks). 
From AD2 to AD3: Bitherapy was not allowed (venlafaxine + escitalopram). A maximum of 
3 days of therapeutic window was allowed. 
 
Procedures 
In the venlafaxine phase of the trial, responders were defined in presence of: 1. at day 28: 
MADRS <20 and decrease from start of the venlafaxine treatment in MADRS total score 
≥25%; or 2. at day 42: MADRS <20 or decrease from start of the venlafaxine treatment in 
MADRS total score ≥50%. 
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In the escitalopram phase of the trial, responders were defined in two ways: 1. at day 84, if 
both of the following criteria were met: a. MADRS <20; b. decrease from start of the 
escitalopram treatment in MADRS total score >25%; 2. at day 84, if both of the following 
criteria were met: a. MADRS <20; b. decrease from start of the escitalopram treatment in 
MADRS total score ≥50%. As primary outcome a MADRS decrease ≥50% has been 
considered while MADRS decrease >25% has been described in Supplementary materials 
(Supplementary table 3).  
In both phases remitters were defined as having a MADRS score <10. 
MADRS ratings have been collected by independent researchers blinded to the study 




To evaluate the efficacy of escitalopram in TRD, assessed by 2 consecutive failed 
antidepressant treatments. The considered primary outcome was the MADRS score. 
Secondary aims 
To evaluate efficacy of escitalopram considering further scales: the HRSD, CGI-S and CGI-I. 
To assess safety and tolerability of escitalopram. 
 
Statistical analyses 
The primary analysis was a repeated-measure ANOVA analysis of variance focused on Day 
14, 28, 42, 56, 70 and 84 MADRS change from baseline (Day 0). Focus was on Intent To 
Treat (ITT) patients, but analyses on completers were also performed. 
The secondary analyses of HRSD, CGI-S and CGI-I change scores from baseline were 
carried out in line with the primary analysis. 
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P-value was set at 0.05 level. The sample had sufficient power (0.80) to detect a small effect 
size (f=0.07) that, as an example, corresponds to a final difference in the total MADRS score 





Four hundred seventeen patients were initially included, the flow chart of patient 
inclusion/exclusion process is reported in Figure 2. Baseline socio-demographic and clinical 
features of the ITT sample are shown in Table 1 (more data are reported in Supplementary 
tables 1 and 2). The sample was mainly composed of outpatients (81.60%). Melancholic 
features were present in 55.80% of patients while current anxiety disorder comorbidity was 




Table 2 shows main outcome data of ITT patients in the two phases of the trial.  
In the first phase of the trial, responders to venlafaxine were 151 (36.21%) while remitters 
were 83 (19.90%). MADRS mean scores at baseline were 31.45±6.24 and at the end of this 
phase of the trial were 19.98±12.20.  
Out of the 183 (43.89%) non responders to venlafaxine, 170 patients (92.90%) were included 
in the second phase of the trial (13 non responders (7.10%) were not included because of 
clinician’s choice or patient refusal to continue the study). 
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In the second phase of the trial, responders to escitalopram were 71 (41.76%) while remitters 
were 39 (22.94%). MADRS mean scores at baseline were 29.82±7.82 and at the end of this 
phase were 18.42±11.09. 
 
MADRS mean scores at each time-point in both phases of the trial are shown in Figure 3, 
with a significant effect of time in the change from baseline scores in both phases 
(venlafaxine phase: F=220.83; d.f.=3, 942; p<0.0001; escitalopram phase: F=98.21; d.f.=3, 
438; p<0.0001).  
 
Data on completers are provided in Supplementary table 3: in particular, in the first phase of 
the trial 334 (80.10%) of 417 patients were completers while in the second phase completers 
were 157 (92.35%) of 170 patients. Considering completers, the mean dosage at the end of 
the venlafaxine phase of the trial was mg 186.79±43.67 while at the end of the escitalopram 
phase was mg 26.43±4.80. 
When missing values were taken into account by using the last observation carried forward 
(ITT - LOCF), and LOCF patients were compared with completers in terms of rates of 
responders/remitters, results did not change (data not shown). Results also showed no change 




The repeated-measure ANOVA showed similar results on the change from baseline on 
HRSD, CGI-S and CGI-I scores in both phases of the trial (venlafaxine phase, respectively: 
F=186.20, p<0.0001; F=20.27, p<0.0001; F=60.47, p<0.0001; escitalopram phase, 
respectively: F=78.81, p<0.0001; F=89.72, p<0.0001; F=82.73, p<0.0001). 
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In the venlafaxine phase of the trial, dropouts were 83 (19.90%) and in the escitalopram 
phase of the trial dropouts were 13 (7.65%).  
At the end of both phases, patients reporting at least one severe side effect (psychic, 
neurologic, autonomic, or another effect) were 80 (19.18%) in the first phase and 35 
(20.59%) in the second one (Table 2 for ITT and Supplementary table 4 for completers). 
In both phases the most frequent side effects were asthenia/lassitude/increased fatigability 
and diminished sexual desire. In the first phase another frequent side effect was reduced sleep 
duration, while in the second phase was increased dream activity. 
In more detail, patients reporting at least one severe psychic side effect were 48 (15.09%) in 
the first phase and 18 (11.46%) in the second one; in particular, patients on venlafaxine 
reported higher rates of concentration difficulties, tension and reduced sleep duration, while 
patients on escitalopram reported higher rates of increased dream activity. Patients reporting 
at least one severe neurologic side effect (dystonia) were only 3 (0.94%), all in the first phase 
of the trial. Patients reporting at least one severe autonomic side effect were 10 (3.14%) in the 
first phase and 8 (5.09%) in the second one; in particular patients on escitalopram reported 
higher rates of increased tendency to sweating. Patients reporting at least one other kind of 
severe side effect were 40 (12.58%) in the first phase and 17 (10.83%) in the second one, 
patients on venlafaxine reporting higher rates of diminished sexual desire.    
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This study was designed to evaluate efficacy and tolerability in a sample of patients resistant 
to at least two adequate (in terms of dose and duration) antidepressant treatments. The main 
finding of the paper is the relevant efficacy of a third treatment in subjects who were resistant 
to two previous treatments. Escitalopram has been suggested in the treatment of severe 
depression (Montgomery, Baldwin et al. 2007), and only one study previously investigated 
this issue in TRD (Lam, Lonn et al. 2010); however this was a retrospective study and 
resistance was defined as non response to only one previous treatment.  
Contrastingly to the STAR*D study, which showed a progressive decrease in treatment 
efficacy with subsequent antidepressant treatments but which focused on chronic depression 
(mean duration of depressive episode was over 150 weeks), the third treatment was 
numerically higher than the second treatment, with the response/remission rates of 
36.21/19.90% for venlafaxine and 41.76/22.94% for escitalopram, which was the third 
treatment.  
Regarding dosage, patients were adequately treated with both venlafaxine (mean dose at the 
end: 186.79±43.67 mg) and escitalopram (mean dose at the end: 26.43±4.80 mg). Dropout 
rate in the escitalopram phase (7.65%) was lower than the one previously reported in MDD 
patients treated with escitalopram compared with nortriptyline in the GENDEP study (Power, 
Muthen et al. 2012).  
Regarding side effect rate, escitalopram appeared to be associated with high tolerability in 
TRD patients. In those with mild side effect severity, the rate in the escitalopram phase was 
lower than previously reported (Bose, Tsai et al. 2012). However, it has to be taken under 
consideration that the method of assessing side effects varies from study to study. Moreover, 
this was an open trial, where side effects are usually lower than in double-blind controlled 
Page 18 of 42
URL: http:/mc.manuscriptcentral.com/swbp - e-mail: wfsbp@meduniwien.ac.at





























































For Peer Review Only
18 
 
trials. In the large post-marketing surveillance study by Laux et al., in which patients with 
comorbid depression and anxiety were treated for 16 weeks with escitalopram, results similar 
to the present were reported regarding higher frequency of fatigue (Laux, Friede et al. 2013).  
There are a number of design issues that may weaken our findings. First of all the open nature 
of the study could be criticised since it may allow physician bias to influence results. 
Secondly, the retrospective assessment of the first antidepressant treatment (AD1) could be 
considered as a limitation. However, the present study is the only naturalistic study which 
used a prospectively defined last venlafaxine treatment to define TRD before treatment with 
escitalopram (the paper is not a comparative study to venlafaxine). The restrictions of the 
exclusion criteria in the patient selection might have led to a well defined study population 
that might not be completely comparable to other patients receiving antidepressants. Another 
limitation is represented by the responder definition in both phases of the trial (MADRS 
decrease from baseline ≥50%). Although this is the most widely used criterion of responders, 
this definition could have reduced response rates in the second phase of the trial and may not 
be the most appropriate definition in a population with defined resistance to treatment. 
Furthermore, the 4 week criteria for the duration of the first antidepressant treatment (AD1) 
might be criticised as being too short in TRD. Some authors suggested to consider a treatment 
period of at least 6 weeks for the initial antidepressant (Bschor and Baethge 2010), 
particularly in TRD to evaluate possible late effects of the treatment. However, guidelines 
(e.g., NICE, United Kingdom) propose that the decision on treatment for TRD should not be 
delayed and should be made at 3 to 4 weeks. Moreover, the possibility to establish efficacy 
within this period in TRD has been previously reported (Rapaport, Gharabawi et al. 2006). 
Moreover, the six week venlafaxine trial may have been insufficient to show eventual 
improvement, considering that venlafaxine may require multiple dose increases to achieve 
multi-receptor effectiveness. Finally, the dosage heterogeneity among patients from different 
Page 19 of 42
URL: http:/mc.manuscriptcentral.com/swbp - e-mail: wfsbp@meduniwien.ac.at





























































For Peer Review Only
19 
 
European countries for both venlafaxine and escitalopram, due to different treatment 
guidelines, could have biased the results.  
The results of the present study showed high response rates and tolerability for a third 
treatment in TRD patients who previously did not respond to at least two previous 
antidepressants. Our results suggest that treatment response and remission may be still 
relevant after a third line antidepressant.  
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Figure 1. Study design schema (AD1: first antidepressant treatment; AD2: second 
antidepressant treatment; AD3: third antidepressant treatment; TRD: treatment resistant 
depression). 
 
Figure 2. Flow chart of the patient inclusion/exclusion process (ITT: intent to treat patients; 
AD1: first antidepressant treatment; AD2: second antidepressant treatment; AD3: third 
antidepressant treatment).  
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Socio-demographic and clinical features ITT patients n=417 
Mean±SD/n(%) 
Age (years, n=416) 47.29±12.51  
Males 




337 (81.60)  
Onset (years, n=334) 
33.22±13.16  




Current anxiety disorder  
97 (23.26) 
 
Table 1. Socio-demographic and clinical features of the Intent To Treat patients (n=417) at baseline. 
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Clinical features ITT Venlafaxine Phase (n=417) 
Mean±SD/n(%) 
ITT Escitalopram Phase (n=170) 
Mean±SD/n(%) 
Response   
Responders 151 (36.21) 71 (41.76) 
Non responders 183 (43.88) 86 (50.59) 
Dropouts 83 (19.90) 13 (7.65) 
Remission    
Remitters  83 (19.90) 39 (22.94) 
Non remitters  251 (60.19) 118 (69.41) 
Dropouts 83 (19.90) 13 (7.65) 
MADRS   
Day 0 – baseline 31.45±6.24  
Day 14 (n=406) 26.85±9.45  
Day 28 (n=366) 22.01±10.67  
Day 42 – end of the venlafaxine phase (n=318) 19.98±12.20  
Day 42 – end of the venlafaxine phase LOCF (n=407) 20.59±12.31  
Day 42 – baseline of the escitalopram phase (n=170)  29.82±7.82 
Day 56 (n=169)  25.67±9.80 
Day 70 (n=163)  21.63±10.31 
Day 84 – end of the escitalopram phase (n=157)  18.42±11.09 
Day 84 – end of the escitalopram phase LOCF (n=170)  19.32±11.39 
UKU   
Presence of at least one side effect (severe)   
Day 42 – end of the venlafaxine phase (n=318) 80 (19.18)   
Day 84 – end of the escitalopram phase (n=157)  35 (20.59) 
 
Table 2. Main outcome measures of the Intent To Treat patients in the two phases of the trial (n=417 and n=170, respectively). 
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Socio-demographic and clinical features Intent To Treat MDD patients n=417 
Mean±SD/n(%) 




































337 (81.60)  
Onset (years, n=334) 
33.22±13.16  




Severe without psychotic features 
216 (53.60) 
Severe with psychotic features 
5 (1.24) 
Duration current episode (days, n=375) 
169.00±194.16 
Number of lifetime episodes (n=310) 
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Duration hospitalization (weeks, n=84) 
13.80±21.02 




Major depressive episode features (n=413) 
 
With full inter-episode recovery 
71 (17.19) 
























Current anxiety disorder  
97 (23.26) 
Current panic disorder  
34 (8.15) 
Current social phobia 
26 (6.23) 
Current obsessive compulsive disorder 
12 (2.88) 
Current post traumatic stress disorder 
8 (1.92) 
Generalized anxiety disorder 
56 (13.43) 
Current alcohol dependence  
3 (0.72) 
Current alcohol abuse 
2 (0.48) 
Current substance dependence 
2 (0.48) 
Current substance abuse 
0 (0.00) 
Current anorexia nervosa 
1 (0.24) 
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Current bulimia nervosa 
3 (0.72) 
Psychiatric antecedents (n=415) 
 












































Supplementary table 1. Socio-demographic and clinical features of the Intent To Treat patients (n=417) at baseline. 
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Antidepressant treatments at inclusion  Intent To Treat MDD patients n=378  
n(%) 
Paroxetine 76 (20.11) 
Sertraline 62 (16.40) 
Citalopram 40 (10.58) 
Fluoxetine 40 (10.58) 
Fluvoxamine 19 (5.03) 
Mirtazapine 33 (8.73)  
Amytriptiline 3 (0.79) 
Clomipramine 11 (2.91) 
Imipramine 2 (0.53) 
Nortriptiline 5 (1.32) 
Trimipramine 2 (0.53) 
Maprotiline 2 (0.53) 
Dosulepine 3 (0.79) 
Reboxetine 2 (0.53) 
Trazodone 7 (1.85) 
Bupropion 4 (1.06) 
Mianserine 7 (1.85) 
Others 60 (15.87) 
Number of previous antidepressants prescribed for 
current or past episode (n=270) 
1.39±1.28 
Number of adequate* previous antidepressants 




Supplementary table 2. Antidepressant treatments at inclusion of the Intent To Treat patients (n=378; n=39 were missing). 
 
* Duration of at least 4 weeks and a score ≥2 at the Modified Antidepressant Treatment History Form (ATHF). 
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Clinical features Completers Venlafaxine Phase 
(n=334) Mean±SD/n(%) 
Completers Escitalopram Phase 
(n=157) Mean±SD/n(%) 
Response   
Responders 151 (45.21) 71 (45.22) (MADRS≥50%) 
86 (54.78) (MADRS>25%) 
Non responders 183 (54.79) 86 (54.78) (MADRS≥50%) 
71 (45.22) (MADRS>25%) 
Remission    
Remitters  83 (24.85) 39 (24.84) 
Non remitters  251 (75.15) 118 (75.16) 
Doses   
Day 0 – baseline 75.00±0.00  
Day 14 (n=406) 122.84±37.96  
Day 28 (n=366) 166.60±42.11  
Day 42 – end of the venlafaxine phase (n=318) 186.79±43.67  
Day 42 – baseline of the escitalopram phase (n=170)  10.00±0.00 
Day 56 (n=169)  22.19±4.15 
Day 70 (n=163)  25.15±5.01 
Day 84 – end of the escitalopram phase (n=157)  26.43±4.80 
HDRS 17 item   
Day 0 – baseline (n=416) 22.34±5.31  
Day 14 (n=406) 18.80±7.03  
Day 28 (n=366) 15.61±7.78  
Day 42 – end of the venlafaxine phase (n=318) 14.43±8.82  
Day 42 – baseline of the escitalopram phase (n=154)  21.40±6.13 
Day 56 (n=169)  18.22±6.94 
Day 70 (n=163)  15.40±7.50 
Day 84 – end of the escitalopram phase (n=157)  13.69±8.33 
CGI-S   
Day 0 – baseline (n=415) 3.05±3.54  
Day 14 (n=406) 4.42±1.11  
Day 28 (n=366) 3.85±1.29  
Page 30 of 42
URL: http:/mc.manuscriptcentral.com/swbp - e-mail: wfsbp@meduniwien.ac.at





























































For Peer Review Only
30 
 
Day 42 – end of the venlafaxine phase (n=318) 3.47±1.58  
Day 42 – baseline of the escitalopram phase (n=154)  4.78±0.86 
Day 56 (n=169)  4.28±1.15 
Day 70 (n=163)  3.79±1.25 
Day 84 – end of the escitalopram phase (n=157)  3.30±1.48 
CGI-I   
Day 14 (n=406) 3.47±1.03  
Day 28 (n=366) 2.94±1.15  
Day 42 – end of the venlafaxine phase (n=318) 2.79±1.37  
Day 42 – baseline of the escitalopram phase (n=154)  3.84±0.87 
Day 56 (n=169)  3.30±0.95 
Day 70 (n=163)  2.82±1.08 
Day 84 – end of the escitalopram phase (n=157)  2.55±1.28 
 
Supplementary table 3. Main outcome measures of Completers in the two phases of the trial (n=334 and n=157, respectively). 
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Side effects (UKU) Completers Venlafaxine Phase 
(n=318) n(%) 
Completers Escitalopram Phase 
(n=157) n(%) 
At least a psychic side effect (moderate-severe) 
  
Day 42 – end of the venlafaxine phase  
120 (37.74)  
Day 84 – end of the escitalopram phase  
 52 (33.12) 
At least a psychic side effect (severe) 
  
Day 42 – end of the venlafaxine phase  
48 (15.09)  
Day 84 – end of the escitalopram phase  
 18 (11.46) 
Psychic side effects (severe) 
  
Concentration Difficulties 
25 (7.86) 8 (5.10) 
Asthenia/Lassitude/Increased Fatigability 
27 (8.49) 10 (6.37) 
Sleepiness/Sedation 
22 (6.92) 9 (5.73) 
Failing Memory 
0 (0.00) 0 (0.00) 
Depression 
23 (7.23) 8 (5.10) 
Tension/lnner Unrest 
10 (3.14) 1 (0.64) 
Increased Duration of Sleep 
2 (0.63) 4 (2.55) 
Reduced Duration of Sleep 
29 (9.12) 7 (4.46) 
Increased Dream Activity 
1 (0.31) 10 (6.37) 
Emotional indifference 
2 (0.63) 3 (1.91) 
At least a neurologic side effect (moderate-severe) 
  
Day 42 – end of the venlafaxine phase  38 (11.95)  
Day 84 – end of the escitalopram phase   14 (8.92) 
At least a neurologic side effect (severe) 
  
Day 42 – end of the venlafaxine phase  3 (0.94)  
Day 84 – end of the escitalopram phase  0 (0.00) 
Neurologic side effects (severe)   
Dystonia 
3 (0.94) 0 (0.00) 
Rigidity 
0 (0.00) 0 (0.00) 
Hypokinesia/Akinesia 
0 (0.00) 0 (0.00) 
Hyperkinesia logic 
0 (0.00) 0 (0.00) 
Tremor 
0 (0.00) 0 (0.00) 
Akathisia 
0 (0.00) 0 (0.00) 
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0 (0.00) 0 (0.00) 
Paraesthesias 
0 (0.00) 0 (0.00) 
At least an autonomic side effect (moderate-severe)   
Day 42 – end of the venlafaxine phase  114 (35.85)  
Day 84 – end of the escitalopram phase   46 (29.30) 
At least an autonomic side effect (severe)   
Day 42 – end of the venlafaxine phase  10 (3.14)  
Day 84 – end of the escitalopram phase   8 (5.09) 
Autonomic side effects (severe)   
Accommodation Disturbances 
1 (0.31) 0 (0.00) 
Increased Salivation 
0 (0.00) 0 (0.00) 
Reduced Salivation 
3 (0.94) 0 (0.00) 
Nausea/Vomiting 
0 (0.00) 0 (0.00) 
Diarrhoea 
0 (0.00) 1 (0.64) 
Constipation 
0 (0.00) 0 (0.00) 
Micturition Disturbances 
0 (0.00) 0 (0.00) 
Polyuria/Polydipsia 
0 (0.00)  0 (0.00) 
Orthostatic Dizziness 
0 (0.00) 0 (0.00) 
Palpitations/Tachycardia 
1 (0.31) 0 (0.00) 
Increased Tendency to Sweating 
5 (1.57) 7 (4.46) 
At least another side effect (moderate-severe)   
Day 42 – end of the venlafaxine phase  117 (36.79)  
Day 84 – end of the escitalopram phase   65 (41.40) 
At least another side effect (severe)   
Day 42 – end of the venlafaxine phase  40 (12.58)  
Day 84 – end of the escitalopram phase   17 (10.83) 
Other side effects (severe) 
  
Rash 
0 (0.00) 0 (0.00) 
Pruritus 
1 (0.31) 0 (0.00) 
Photosensitivity 
0 (0.00) 0 (0.00) 
Increased Pigmentation 
0 (0.00) 0 (0.00) 
Weight gain 
0 (0.00) 2 (1.27) 
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1 (0.31) 0 (0.00) 
Menorrhagia 
1 (0.31) 0 (0.00) 
Amenorrhoea 
1 (0.31) 0 (0.00) 
Galactorrhoea 
0 (0.00) 0 (0.00) 
Gynaecomastia 
0 (0.00) 0 (0.00) 
Increased Sexual Desire 
0 (0.00) 0 (0.00) 
Diminished Sexual Desire 
30 (9.43) 11 (7.01) 
Erectile Dysfunction 
6 (1.89) 4 (2.55) 
Ejaculatory Dysfunction 
6 (1.89) 2 (1.27) 
Orgasmic Dysfunction 
12 (3.77) 8 (5.09) 
Dry Vagina 
0 (0.00) 0 (0.00) 
Headache 
6 (1.89) 1 (0.64) 
Physical Dependence 
0 (0.00) 0 (0.00) 
Psychic Dependence 
0 (0.00) 0 (0.00) 
 
Supplementary table 4. Side effects of Completers in the two phases of the trial (n=318 and n=157, respectively). 
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Study design schema (AD1: first antidepressant treatment; AD2: second antidepressant treatment; AD3: 
third antidepressant treatment; TRD: treatment resistant depression).  
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Flow chart of the patient inclusion/exclusion process (ITT: intent to treat patients; AD1: first antidepressant 
treatment; AD2: second antidepressant treatment; AD3: third antidepressant treatment).  
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MADRS mean scores of ITT patients in both phases of the trial.  
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